Ocrelizumab is a humanised monoclonal antibody which blocks the action of a protein called CD20, found on mature B cells. Because of this it is immunosuppressive.

Phase 3 clinical trials of it in the context of MS look very encouraging. It is currently under consideration by the FDA for regulatory approval. There is more about this here; https://www.mssociety.org.uk/ms-rese...ne/ocrelizumab.